

**2021 Financial Conflict of Interest Annual Collection**  
**TRIALS LISTING WITH RELEVANT COMPANY/COMMERCIAL ENTITY**  
**All Trials NOT Permanently Closed**

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/Commercial entity
<b>BRAIN</b>					
CE5	Primary Chemotherapy with Temozolomide vs. Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study	Closed	IG Led	No	Merck, Schering
CE5S	Socio-behavioral Study: Work, Marriage/Social Support, Anxiety and Depression	Closed	CCTG-Led	No	No commercial entity
CE7	A Phase III Trial of Stereotactic Radiosurgery compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases	Open	CCTG-Led	Yes	No commercial entity
CE8	A Phase III Trial of Marizomib in Combination with Standard Temozolomide-Based Radio Chemotherapy versus Standard Temozolomide-Based Radio Chemotherapy Alone in Patients with Newly-Diagnosed Glioblastoma	Closed	IG Led	No	Celgene
CEC1	Phase III Trial On Concurrent And Adjuvant Temozolomide Chemotherapy In Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial	Closed	IG Led	Yes	Merck, Schering
CEC2	Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma	Closed	IG Led	Yes	Merck, Schering
CEC5	Phase II Study of Corticosteroid + Bevacizumab vs Corticosteroid + Placebo (BeST) for Radionecrosis after Radiosurgery for Brain Metastases	Closed	IG Led	Yes	Hoffman-La Roche/Genentech
CEC6	Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma	Open	IG Led	Yes	Merck, Schering
CEC7	Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease	Open	IG Led	Yes	No commercial entity
<b>BREAST</b>					
MA26	Phase III Trial of Observation +/- Tamoxifen Vs. Rt +/- Tamoxifen For Good Risk Duct Carcinoma In-Situ (DCIS) of The Female Breast	Closed	IG Led	Yes	No commercial entity
MA32	A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer	Closed	CCTG-Led	Yes	Apotex Inc.
MA32D	Change In Mammographic Density with Metformin Use: A Companion Study to NCIC CTG Study MA.32	Closed	IG Led	Yes	No commercial entity
MA32F	Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer (NCIC CTG MA.32 Ancillary Study led by the National Surgical Adjuvant Breast and Bowel Project)	Closed	IG Led	Yes	No commercial entity
MA33	A Randomised Phase III Study Of Radiation Doses And Fractionation Schedules For Ductal Carcinoma In Situ (DCIS) Of The Breast	Closed	IG Led	No	No commercial entity
MA34	A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer	Closed	IG Led	No	Hoffmann-La Roche Limited
MA36	A Randomised, Double-Blind, Parallel group, Placebo-Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy	Closed	IG Led	No	AstraZeneca
MA37	PALLAS: PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Adjuvant Endocrine Therapy versus Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer	Closed	IG Led	No	Pfizer
MA38	Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer	Closed	CCTG-Led	No	Pfizer

MA39	Tailor RT: A Randomized Trial of Regional Radiotherapy in Node Positive Luminal A Breast Cancer	Open	CCTG-Led	Yes	No commercial entity
MA40	A Double Blind Placebo Controlled Randomized Phase III Trial of Ipatasertib in Combination with Fulvestrant as Immediate Treatment for Metastatic Estrogen Receptor Positive (ER+) and HER-2 Negative Breast Cancer post CDK4/6 Inhibitor and Aromatase Inhibitor	Open	CCTG-Led	No	Roche
MA41	De-Escalation of adjuvant Chemotherapy in HER-2 positive, Estrogen receptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blockade (DFCRESCENDO)	Planned	IG Led	No	No commercial entity
MAC4	A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer	Closed	IG Led	Yes	Pfizer (exemestane)
MAC5	A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer	Closed	IG Led	Yes	Pfizer (exemestane)
MAC9	Prognostic Factor Panel to Predict Preferred Therapy for Node-Positive Postmenopausal Breast Cancer Patients	Closed	IG Led	Yes	Bayer Schering Pharma (Clodronate), Roche (ibandronate), Novartis (zoledronic acid)
MAC11	A Phase III Trial of Continuous Schedule AC + G vs Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer.	Closed	IG Led	Yes	AMGEN (darbepoetin filgrastim, peg filgrastim);
MAC12	Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial	Closed	IG Led	Yes	Genomic Health
MAC13	Adjuvant, Lapatinib and/or Trastuzumab Treatment Optimisation Study A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer	Closed	IG Led	Yes	GlaxoSmithKline; Roche/Genentech
MAC14	A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer	Closed	IG Led	Yes	No commercial entity
MAC15	A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer	Closed	IG Led	Yes	Genomic Health
MAC18	POSITIVE: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy	Closed	IG Led	Yes	No commercial entity
MAC19	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1 -3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy	Open	IG Led	Yes	No commercial entity
MAC20	Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer	Open	IG Led	Yes	Nestle
MAC21	Aspirin for Breast Cancer (ABC): Randomized Trial of Aspirin as Adjuvant Therapy for Node Positive Breast Cancer	Closed	IG Led	Yes	Bayer
MAC22	Tomosynthesis Mammographic Imaging Screening Trial (TMIST)	Open	IG Led	Yes	No commercial entity
MAC23	Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation with Breast Reconstruction	Open	IG Led	No	No commercial entity
MAC24	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >= 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy	Open	IG Led	Yes	Merck
MAC25	Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/ Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Cancer	Open	IG Led	Yes	Eli Lilly
MAC26	A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer	Open	IG Led	Yes	AztraZeneca
<b>GASTROINTESTINAL</b>					
CO21	A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE).	Open	CCTG-Led	No	No commercial entity
CO26	A Phase II/III Trial of Durvalumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies	Closed	CCTG-Led	No	AstraZeneca

CO27	Irinotecan and Oxaliplatin for Colon cancer in the Adjuvant Setting: mFOLFIRINOX triplet chemotherapy for high-risk stage III colon cancer in <u>adjuvant setting (IROCAS study): A Phase III Randomised Trial</u>	Open	IG Led	No	No commercial entity
CO28	Neoadjuvant chemotherapy and Transanal Excisional MicroSurgery in Early <u>Rectal Cancer- The NeoTEM5 Study</u>	Closed	CCTG-Led	No	No commercial entity
CO29	Circulating Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study ( <u>DYNAMIC III</u> )	Planned	IG Led	No	No commercial entity
CRC3	A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the <u>Prognostic Value of Molecular Markers</u>	Closed	IG Led	Yes	Sanofi-Aventis; Hoffmann-La Roche/Genentech
CRC6	A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer	Closed	IG Led	Yes	Sanofi-Aventis; Pfizer
CRC7	A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision ( <u>PROSPECT</u> )	Closed	IG Led	Yes	No commercial entity
CRC8	A Randomized Phase II Study of Nivolumab after Combined Modality Therapy ( <u>CMT</u> ) in High-Risk Anal Cancer	Open	IG Led	Yes	Nivo, BMS
CRC9	Phase II/III Study of Circulating Tumor DNA as a Predictive Marker for Response to Adjuvant Chemotherapy in Patients with Stage II Colon Cancer	Open	IG Led	Yes	No commercial entity
GA1	A Randomized Phase II/III Trial of Preoperative Chemoradiotherapy versus Preoperative Chemotherapy For Resectable Gastric Cancer ( <u>TOPGEAR</u> )	Open	IG Led	No	Novartis
GA3	A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer ( <u>AGOC</u> )	Open	IG Led	No	Bayer Healthcare Pharmaceuticals
HE1	Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases	Open	CCTG-Led	No	No commercial entity
NEC3	Prospective Randomized Phase II Trial of Pazopanib (NSC# 737754, IND 75648) Versus Placebo in Patients with <u>Progressive Carcinoid Tumors</u>	Closed	IG Led	Yes	Novartis
PA6	Multicentre Randomized Phase III Trial Comparing 6-Month Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolflirinox) In Patients With Resected Pancreatic <u>Adenocarcinoma</u>	Closed	IG Led	No	Sanofi-Aventis Inc.
PA7	A Randomized Phase II/III Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel and Durvalumab or Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st line therapy in Metastatic Pancreatic <u>Adenocarcinoma</u>	Closed	CCTG-Led	No	AstraZeneca
PAC3	Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer	Planned	IG Led	Yes	No commercial entity
<b>GENITOURINARY</b>					
BL13	A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab to Treat Patients with Muscle-Invasive Bladder Cancer	Open	CCTG-Led	No	AstraZeneca
BL13F	Electronic 'Real-Time' Patient Self-Reporting of Immunotherapy Symptomatic Adverse Events using the SYMPTOM-IQ Tool on the uMotif Mobile Health Application (APP): A Prospective Feasibility Sub-Study of BL13 e-PRISM	Open	CCTG-Led	No	AstraZeneca, uMotif
BLC1	A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical <u>Cystectomy For Muscle Invasive Urothelial Cancer</u>	Closed	IG Led	Yes	No commercial entity
BLC4	Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive <u>Bladder Cancer</u>	Closed	IG Led	Yes	Genentech
GCC1	A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours	Open	IG Led	Yes	No commercial entity
PNC1	InPACT: International Penile Advanced Cancer Trial	Open	IG Led	No	No commercial entity
PR13	RADICALS: Radiotherapy and Androgen Deprivation In Combination After Local Surgery	Closed	IG Led	No	Sanofi; AstraZeneca; Schering; Abbvie; Aventis
PR17	Randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation <u>Therapy for Metastatic Prostate Cancer: ENZAMET</u>	Closed	IG Led	No	ASTELLAS
PR19	A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer	Open	CCTG-Led	No	No commercial entity
PR20	A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive <u>Oligometastatic Prostate Cancer [PLATON]</u>	Open	CCTG-Led	No	TerSera Therapeutics LLC

PR21	PLUDO (Prostate Lutetium/Docetaxel): A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease	Open	CCTG-Led	No	EndoCyte and/or Novartis
PR22	DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate. A Randomized Phase III Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localized Prostate Cancer	Open	IG Led	No	Bayer
PRC3	A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer	Closed	IG Led	Yes	Sanofi-Aventis
PRC4	Phase III Trial of Enzalutamide (NSC#766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer	Closed	IG Led	Yes	ASTELLAS; Janssen
REC2	ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma	Closed	IG Led	Yes	Pfizer, Bayer
REC3	A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal	Closed	IG Led	Yes	Pfizer, Exelixis, AstraZeneca
REC4	A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)	Open	IG Led	Yes	BMS
<b>GYNECOLOGY</b>					
CX5	A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer (SHAPE)	Closed	CCTG-Led	No	No commercial entity
CX6	International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer SENTICOL III	Open	IG Led	No	No commercial entity
EN7	Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma	Closed	IG Led	No	No commercial entity
ENC1	A Randomized Phase III Study of Carboplatin and Paclitaxel with or without Pembrolizumab for Measurable Stage 3 or 4A, Stage 4B or Recurrent Endometrial Cancer	Open	IG Led	Yes	Pembro, Merck
OV25	A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer with BRCA 1 and 2 Mutations (STICs and STONEs)	Open	CCTG-Led	No	Apotex Inc.
OV26	An International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Patients with Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy	Open	IG Led	No	AstraZeneca
OV27	Immune Therapy in Clear Cell Ovarian Cancer (ITICC)	Planned	CCTG-Led	No	No commercial entity
OVC1	A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Closed	IG Led	Yes	AstraZeneca
OVC2	A Randomized Phase II/III study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	Closed	IG Led	Yes	AstraZeneca
<b>HEAD AND NECK</b>					
HN9	Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Maintenance Durvalumab versus Durvalumab plus Radiotherapy followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)	Open	CCTG-Led	No	AstraZeneca
HN10	A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma	Open	CCTG-Led	No	No commercial entity
HN11	SPECT-CT Guided Elective Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT): A Phase III Randomized Controlled Trial	Planned	CCTG-Led	No	No commercial entity
HNC2	Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin	Open	IG Led	Yes	Durva, AstraZeneca
<b>HEMATOLOGY</b>					

AL5	Dana Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Adult Consortium Trial: Adult ALL Trial	Closed	IG Led	Yes	Sigma Tau (Baxter), Novartis
AL6	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with AML	Planned	CCTG-Led	No	No commercial entity
ALC2	A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML)	Closed	IG Led	Yes	Novartis
ALC3	A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)	Closed	IG Led	Yes	Merck
ALC4	A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.	Closed	IG Led	Yes	Amgen
ALC6	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL	Open	IG Led	No	Pfizer
CL3	A Genetic, Risk-Stratified Randomized Phase II Study of Four Fludarabine/Antibody Combinations For Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia	Closed	IG Led	Yes	Celgene Corporation
CL4	Randomized Phase II Evaluation of Lower-dose (3-2-1 strategy) vs Full Dose of Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia	Planned	CCTG-Led	No	No commercial entity
CLC2	A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (>= to 65 years of age) with Chronic Lymphocytic Leukemia (CLL)	Closed	IG Led	Yes	Lundbeck Canada Inc. Teva Oncology
CLC2E	A Prospective Economic Analysis of NCIC CTG CLC.2/ALLIANCE A041202: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab versus Ibrutinib Plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (>= 65 Years of Age) With Chronic Lymphocytic Leukemia	Closed	CCTG-Led	No	Janssen Inc.
HD8	BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin's Lymphoma	Closed	IG Led	No	No commercial entity
HD10	A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma	Planned	IG Led	No	Seattle Genetics
HD11	A Randomized Phase II Trial of Pembrolizumab and Brentuximab Vedotin versus GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma	Planned	CCTG-Led	No	Merck, Seattle Genetics
HDC1	A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma	Open	IG Led	Yes	Seattle Genetics
LY12	A Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Compared to Dexamethasone, Cytarabine, and Cisplatin Plus/Minus Rituximab [(R) -GDP VS (R) -DHAP] as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab Versus Observation.	Closed	CCTG-Led	No	Eli Lilly, Roche
LY16	A Phase III Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma	Closed	IG Led	No	Celgene
LY17	A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma	Open	CCTG-Led	No	Janssen Inc.
LY18	An Open-Label Phase I Dose-Escalation Study of Venetoclax in Combination with Rituximab, Gemcitabine, Dexamethasone and Cisplatin in Patients with Relapsed or Refractory Diffuse Large B cell Lymphoma	Hold	CCTG-Led	No	AbbVie, Roche
LYC1	Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB -> R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV -> R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB -> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV -> LR)	Closed	IG Led	Yes	Lundbeck Canada Inc. Teva Oncology

MDC1	A Randomized Phase II/III Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)	Closed	IG Led	Yes	Merck, Celgene
MYC2	Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)	Planned	IG Led	Yes	No commercial entity
MYX1	A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma 1-3 Prior Therapies	Closed	IG Led	No	Onyx; MCRN (Myeloma Canada)
<b>INVESTIGATIONAL NEW DRUG</b>					
I206	A Phase II Study of Sunitinib or Temozolimus in Patients with Advanced Rare Tumours	Closed	CCTG-Led	No	Pfizer Canada Inc.
I214	A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients with Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours	Closed	CCTG-Led	No	OHRI, Turnstone
I217	A Phase I and Enrichment Study of Low-Dose Metronomic Topotecan and Pazopanib in Pediatric Patients with Recurrent or Refractory Solid Tumours Including CNS Tumours	Closed	IG Led	No	Novartis
I223	A Phase II Study of Ribociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer	Open	CCTG-Led	No	Novartis
I224	A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of Patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	Closed	CCTG-Led	No	Novartis
I226	A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given with or without Standard Chemotherapy Regimens	Closed	CCTG-Led	No	AstraZeneca
I227	A Phase II Randomized Study of Pembrolizumab Alone or in Combination with Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma	Closed	CCTG-Led	No	Merck
I228	A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours	Closed	CCTG-Led	No	AstraZeneca
I231	A Phase I/II Study of CX5461	Closed	CCTG-Led	No	Senhwa Biosciences
I232	A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer	Closed	CCTG-Led	No	AstraZeneca
I234	Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol	Open	CCTG-Led	No	AstraZeneca, Bayer
I234A	A Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234	Open	CCTG-Led	No	AstraZeneca
I234B	A Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234	Open	CCTG-Led	No	AstraZeneca
I234C	A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234	Open	CCTG-Led	No	Bayer
I234D	A Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Open	CCTG-Led	No	No commercial entity
I234E	A Phase II Study of Ipatasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with PI3K Pathway Alterations in Circulating Tumour DNA (ctDNA)	Open	CCTG-Led	No	Roche
I234F	A Phase II Study of Durvalumab and Tremelimumab in Metastatic Castration-Resistant Prostate Cancer	Open	CCTG-Led	No	AstraZeneca
I234G	A Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer	Open	CCTG-Led	No	No commercial entity
I235	A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination with Ipilimumab for the Treatment of Patients with Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay	Closed	CCTG-Led	No	BMS
I236	A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination with Weekly Paclitaxel in Patients with Advanced/Metastatic HER2-Negative Breast Cancer	Hold	CCTG-Led	No	UHN
I237	A Phase II Study of CFI-400945 in Patients with Advanced/Metastatic Breast Cancer	Open	CCTG-Led	No	UHN
I238	A Phase II Study of Durvalumab Retreatment in Patient who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity	Open	CCTG-Led	No	AstraZeneca

I239	A Multicenter Phase Ib/II Study of a Polo-Kinase 4 Inhibitor CFI-400945 + the PD-L1 Inhibitor Durvalumab in Patients with Triple Negative Breast Cancer (TNBC)	Open	CCTG-Led	No	AstraZeneca
I240	An Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC)	Planned	CCTG-Led	No	AstraZeneca, BioAtla
I240A	A Phase II Study of Durvalumab and BA3011, A CAB-AXL-ADC in Patients with Platinum Resistant High Grade Serous Ovarian Cancer	Planned	CCTG-Led	No	AstraZeneca, BioAtla
I240B	A Phase II Study of Durvalumab and BA3021, A CAB-ROR2-ADC in Patients with Platinum Resistant High Grade Serous Ovarian Cancer	Planned	CCTG-Led	No	AstraZeneca, BioAtla
<b>LUNG</b>					
BR31	A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer	Closed	CCTG-Led	No	AstraZeneca, MedImmune
BR34	A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab +/- Platinum Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Closed	CCTG-Led	No	AstraZeneca
BR36	A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with Non-Small Cell Lung Cancer	Open	CCTG-Led	No	PGDx
BRC2	A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)	Closed	IG Led	Yes	Roche/Genentech
BRC2E	A Prospective Economic Analysis of NCIC CTG BRC.2/E1505 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)	Closed	CCTG-Led	No	Roche/Genentech
BRC5	A Phase III Randomized Trial of Lobectomy Versus Sublobular Resection For Small, (<= to 2cm) Peripheral Non-Small Cell Lung Cancer	Closed	IG Led	Yes	No commercial entity
BRC6	Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer	Closed	IG Led	Yes	MedImmune (Astra Zeneca), Genentech, Pfizer, Astra Zeneca, BMS
BRC6B	A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Closed	IG Led	No	Genentech (Roche)
BRC6C	A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Closed	IG Led	No	Pfizer
BRC6D	A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Closed	IG Led	No	AstraZeneca
BRC6F	A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)	Closed	IG Led	No	AstraZeneca
BRC6G	A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)	Closed	IG Led	No	Medivation
BRC6I	A Phase III Randomized Study of Nivolumab plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)	Closed	IG Led	No	BMS
BRC7	EA5163/S1709 INSIGNA: A Randomized, Phase III Study of First line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis	Open	IG Led	Yes	No commercial entity
BRC8	A Randomized Phase III Trial of MRI Surveillance with or without Prophylactic Cranial Irradiation in Small-Cell Lung Cancer	Open	IG Led	Yes	No commercial entity
<b>MELANOMA</b>					
ME10	Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2b N0, T3a-bN0, T4a-b N0, and T1-4, N1a, 2a (microscopic) Melanoma	Closed	IG Led	Yes	Merck
ME13	A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)	Open	CCTG-Led	No	No commercial entity
ME15	Melanoma Margins Trial II - A Phase III, Multi-centre Randomized Controlled Trial Investigating 1cm vs 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (MelMarT-II)	Open	IG Led	No	No commercial entity
MEC3	A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma	Closed	IG Led	Yes	BristolMyersSquibb
MEC5	A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma	Closed	IG Led	Yes	Merck
<b>SARCOMA</b>					

SR7	A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)	Planned	IG Led	No	No commercial entity
SRC6	Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib	Closed	IG Led	Yes	Novartis
SRC7	A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)	Closed	IG Led	Yes	Bayer
<b>SUPPORTIVE CARE</b>					
SC24	A Phase II Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases	Closed	CCTG-Led	No	No commercial entity
SC26	Emotion and Symptom-focused Engagement (EASE): A Randomized Controlled Trial for Individuals with Acute Leukemia	Open	CCTG-Led	No	No commercial entity
SC27	Living with Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors	Open	CCTG-Led	No	No commercial entity
SC28	The SEEMLESS Study: A randomized trial of a Smartphone App-based MindfulnEss intervention for cancer survivors	Planned	CCTG-Led	No	No commercial entity
<b>OTHER</b>					
CT1	A Single-arm, Multicentre Trial of Decentralized CD19 CAR T-cell Manufacturing and Therapy in Patients with Relapsed/Refractory Aggressive B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia	Planned	IG Led	No	No commercial entity
IC8	COV-IMMUNO - A Randomized, Phase III Trial of Immunization with IMM-101 versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure	Open	CCTG-Led	No	Immodulon
ICC1	NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study	Open	IG Led	Yes	No commercial entity
<b>PRECISION MEDICINE</b>					
PM1	Canadian Profiling and Targeted agent Utilization tRIal (CAPTUR)	Open	CCTG-Led	No	BMS, Roche, Pfizer, AstraZeneca
PM1S	Insight of the Use and Value of Genomic Analysis in Cancer Patients: A Pan-Canadian Survey of Oncologists and Patients	Open	CCTG-Led	No	Roche